Chronic Lymphocytic Leukemia: ASCO Tumor Boards

This is a case-based activity that includes discussion of a 43-year old female with newly diagnosed Chronic Lymphocytic Leukemia (CLL), diagnosed in 2012, initially managed with observation.  In February 2014, the patient comes for a follow-up with no symptoms. The patient completes six cycles of FCR and enters a complete remission, albeit MRD positive. She is serially observed, and two years later returns to clinic with the following lab results:WBC 25, HgB 11, Platelets 110,000.  This case presentation engages users to consider best next steps as the faculty lead in discussion. 

Learning Objectives

  • Assess the efficacy and toxicity of novel small molecule inhibitors for Chronic Lymphocytic Leukemia
  • Evaluate advantages of chemo-immunotherapy in front line therapy of selected patients with low risk CLL
  • Review the role of specific CLL –related risk factors for choice of appropriate CLL therapy in the front-line setting

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on May 20, 2018. Participants must complete all necessary course components by this date to receive credit.